Search

News Effect of PCSK9 Inhibitors on Clinical Outcomes in Patients with Hypercholesterolemia –⁠ Meta-Analysis of 35 Randomized Controlled Trials

The authors from several American institutions examined the efficacy and safety of two proprotein convertase subtilisin/kexin type 9 (PCSK9i) inhibitors, alirocumab and evolocumab, in their work. They conducted a systematic meta-analysis of randomized controlled clinical trials comparing the administration of these two PCSK9i with standard treatment.

Source: Hypercholesterolemia 25. 11. 2021

News INTERACTIVE CASE STUDY: Treatment of glaucoma medications without preservatives –⁠ current trend

The use of glaucoma medications without preservatives has been a trend in recent years. You can try their clinical application in the role of a prescribing doctor in an interactive case study. Practical information about this popular local treatment is based on the evidence-based medicine foundation, provided by its author MUDr. Petr Výborný, CSc., from the Eye Clinic of the 1st Faculty of Medicine, Charles University and University Military Hospital in Prague.

Source: Treatment of Glaucoma 28. 9. 2023

News Risk of Venous Thromboembolism and CV Events during Targeted Treatment of Nonspecific Bowel Inflammations

Authors of a freshly published study based on real-world data from the USA investigated whether there are differences in the risk of venous thromboembolism (VTE) and major cardiovascular (CV) events in patients with nonspecific bowel inflammations (IBD) who were newly prescribed the Janus kinase inhibitor (JAK) tofacitinib or the tumor necrosis factor-alpha (TNF-α) inhibitor.

Source: Intestinal Inflammations 22. 8. 2022

Články časopisu Treatment of bleeding caused by liver cirrhosis-associated portal hypertension –⁠ update of Czech Society of Hepatology guidelines

Author of the article: T. Fejfar, T. Vaňásek, R. Brůha, P. Hůlek, V. Procházka, J. Petrtýl, J. Lata Source: Gastroenterologie a hepatologie | 2/2017 21. 4. 2017

News Lorlatinib in a Patient with Meningeal Carcinomatosis –⁠ Case Report

The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report demonstrates how a targeted mechanism of action and optimal drug penetration into the central nervous system (CNS) can not only quickly relieve patients from neurological problems associated with meningeal infiltration, but also prolong their survival.

Source: Genetic Profile and Treatment of NSCLC 6. 11. 2022

News Sotorasib in the Treatment of a Patient with NSCLC and DIC –⁠ A Case Report

Sotorasib is the first clinically used inhibitor of the KRAS oncogene with the G12C mutation. Its efficacy in the targeted treatment of non-small cell lung cancer (NSCLC) is still under research, but it is expected to bring significant benefits. The effect of sotorasib in a patient with a low baseline performance status (PS) and active brain metastases is presented in the following case report.

Source: Lung Cancer 24. 5. 2023

News EULAR 2023: What Do CRP Levels Reveal About the Efficacy and Safety of Tofacitinib in Patients with Ankylosing Spondylitis?

What is the impact of baseline C-reactive protein (CRP) levels on the efficacy and safety of treating ankylosing spondylitis (AS) with the Janus kinase inhibitor (JAKi) tofacitinib? The authors of the cited study below sought to answer this question, with their results presented at this year’s annual EULAR congress, which took place in Milan, Italy, at the traditional turn of May and June.

Source: Arthritis 22. 8. 2023

News Recommendations for Substitution Therapy with Immunoglobulins in Hemato-oncological Patients with Secondary Immunodeficiency –⁠ Expert Consensus According to the DELPHI Methodology

Substitution therapy with immunoglobulins is used not only for patients with primary immunodeficiencies. Below, we briefly summarize recommendations concerning hemato-oncological patients with secondary immunodeficiency.

Source: Primary and Secondary Immunodeficiencies 1. 12. 2021

News How Common is Alpha-1 Antitrypsin Deficiency?

What is the prevalence of alpha-1 antitrypsin deficiency (AATD)? What comorbidities are associated with it? Are healthcare costs for these patients higher compared to patients with unrelated obstructive lung diseases? Awareness of AATD is low and prevalence data are only indicative. The authors of a study published in the European Respiratory Journal aimed to map this disease in a population of 4 million German insured individuals.

Source: Deficiency of Alpha-1-Antitrypsin 17. 12. 2020

News Intravenous Thrombolysis in Ischemic Stroke Patients on Dabigatran Treatment

What are the outcomes of performing intravenous thrombolysis in patients with acute ischemic stroke after reversing the anticoagulant effect of dabigatran with idarucizumab? The answer is provided by a data analysis from real-world clinical practice in stroke centers, published by Czech authors.

Source: Anticoagulant Treatment 18. 2. 2021

News Is Adding Fibrinogen Concentrate to Transfusion Therapy for Postpartum Hemorrhage an Effective Approach?

Significant postpartum hemorrhage can be managed with fresh frozen plasma transfusion. However, administering larger volumes is associated with several risks. The authors of the Japanese study below investigated whether fibrinogen concentrate added to fresh frozen plasma transfusions is an effective tool in reducing the need for erythrocyte concentrate and whether it helps prevent complications of intensive transfusion therapy.

Source: Life-threatening Bleeding 20. 5. 2022

News Predictors and Rate of Anticoagulant Therapy Discontinuation in Patients with Atrial Fibrillation

With the worldwide increase in the prevalence of atrial fibrillation (AF), the use of anticoagulants (warfarin, DOACs –⁠ direct oral anticoagulants) to reduce the risk of ischemic stroke (iCMP) is also rising. However, continuous use is essential. An Australian study analyzed available national data to investigate the rate of therapy discontinuation for individual anticoagulants and the predictors of persistence on treatment.

Source: Anticoagulant Treatment 25. 5. 2023

News Inhibitor of Activated Factor XII Garadacimab in Prophylaxis of HAE Attacks

Hereditary angioedema (HAE) is an autosomal dominant inherited disease characterized by a deficiency of C1 inhibitor. This condition leads to excessive production of bradykinin, which is responsible for the development of soft tissue edema. Garadacimab represents a human antibody, the first of its class, aimed at inhibiting activated factor XII, a key initiator of bradykinin formation. The phase II study presented below, whose results were recently published, evaluated the efficacy and safety of this innovative HAE therapy.

Source: Hereditary Angioedema 14. 11. 2022

News Cenobamate in the Therapy of Pharmacoresistant Epilepsy in a Warfarinized Patient –⁠ A Case Study

A case study from Czech practice presents a patient with pharmacoresistant epilepsy and concurrent warfarin medication for heart valve replacement, where the INR value remained within the cardiologist’s recommended range without further adjustments to anticoagulant therapy during combined antiepileptic therapy with cenobamate (CNB) under the recommended dose titration.

Source: Epilepsy 13. 9. 2023

News Treatment of a patient with colorectal cancer after kidney transplantation –⁠ case report

Patients after organ transplantation currently live to an older age thanks to advances in surgery and pharmacotherapy. However, the longer a person takes immunosuppressants, the more they are at risk of developing malignant disease. The case report of Hungarian doctors from the university hospital in Pécs illustrates what the treatment of metastatic colorectal cancer (mCRC) after kidney transplantation can look like.

Source: Colorectal Cancer 20. 5. 2022